The stock will trade on ASCO 2026 data (May 29-June 2) and the Q3 2026 dosing study initiation, not on the quarterly loss. Monitor for interim analysis readout from FORTIFI-HN01 expected mid-2027. The $539.8M cash position removes near-term financing risk.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $22.92entry
- T+1 · 6mo ago −2.36%α −2.22% · $22.38
- T+5 · 6mo ago −15.84%α −15.75% · $19.29
- T+20 · 5mo ago −10.30%α −9.99% · $20.56
- T+60 · 3mo ago +12.96%α +8.57% · $25.89
Price Chart
How similar events traded
Executive Summary
Bicara Therapeutics reported Q1 2026 net loss of $56.2M ($-0.93/share), wider than the $-0.68 loss in Q1 2025, driven by increased R&D spend on the FORTIFI-HN01 pivotal trial. The company has $539.8M in cash, extended runway into H1 2029, and announced key clinical and executive milestones including a planned Q3 2026 randomized dosing study and ASCO 2026 data presentation. This is a pre-revenue clinical-stage biotech, the widening loss is expected and not a surprise; the stock will move on clinical catalysts, not quarterly financials.
Key Financial Metrics
Key Facts
- Net loss of $56.2M for Q1 2026 vs $36.8M in Q1 2025
- Cash, cash equivalents and marketable securities of $539.8M as of March 31, 2026
- Cash runway extended into first half of 2029
- Plan to initiate randomized study of loading + Q3W maintenance dosing in Q3 2026
- Long-term follow-up data from Phase 1b to be presented at ASCO 2026 (May 29-June 2)
- Bill Schelman promoted to CMO; Chris Sarchi appointed as Chief Commercial Officer
- R&D expenses $47.5M in Q1 2026 vs $34.3M in Q1 2025
- Net loss per share $-0.93 vs $-0.68 in prior year period
Financial Impact
Net loss widened by $19.4M YoY to $56.2M; cash position $539.8M provides runway into H1 2029
Risk Factors
- Clinical trial failure or disappointing ASCO data
- Dilution risk if additional financing needed before potential approval
- Regulatory delays in dosing study or accelerated approval pathway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033135 |
| Document: bcax-20260511.htm | 0001628280-26-033135 |
| Document: 0001628280-26-033135-index-headers.html | 0001628280-26-033135 |
| Document: 0001628280-26-033135-index.html | 0001628280-26-033135 |
| Document: 0001628280-26-033135.txt | 0001628280-26-033135 |
| 8-K Data (Synthetic) | 0001628280-26-033135 |
Track record
26 reports on BCAX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers